Loading…
Loading…
California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ: MRNA) by 31.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company's stock after purchasing an additional 149,192 shares during the quarter. California Public Employees
Moderna is racing towards an important approval. But it may not move the stock higher.
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for MRNA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.